Nigerian Tribune’s Post

🗓️In February, POLITICO Europe will host "The Critical Medicines Act: How can Europe achieve drug supply sovereignty?", an event presented by Teva Pharmaceuticals Adrian van den Hoven, Director General of Medicines for Europe, will participate in a panel discussion. The Covid-19 pandemic revealed weaknesses in the EU's medicines market, from fragile supply chains to insufficient solidarity. The EU Critical Medicines Act aims to secure medicine supplies by diversifying sources and boosting Europe’s production of generics and APIs. What should the Critical Medicines Act prioritize to strengthen supply chains and industrial capacity? Experts will discuss reshoring, market incentives, stockpiling risks, and the role of public tools to ensure Europe’s health resilience. Want to follow the discussion online? Follow this link:

The European Medicines Agencies (EMA) and Heads of Medicines Agencies (HMA) joint strategy for 2028 marks a pivotal moment for life sciences management. This call for consultation underscores the critical need to adapt to a rapidly evolving medicines landscape, shaped by new legislation, technological innovations like AI, and emerging public health threats. For the life sciences sector, this strategy presents both challenges and opportunities—particularly in improving access to medicines, leveraging digital advancements for efficiency, and fostering a regulatory environment that enhances innovation and competitiveness. As EMA and HMA focus on sustainability, antimicrobial resistance, and medicines availability, the life sciences industry must engage proactively to ensure alignment with these strategic objectives. The consultation offers stakeholders a chance to influence how regulatory frameworks evolve to support cutting-edge advancements while addressing societal health needs. Ultimately, this strategy will shape the future of pharmaceutical development and regulation across the EU, making stakeholder input crucial for driving impactful, forward-thinking change. #regulatorygramwrok#healthneeds#EMA#sciencemanagement#lifesciencesindustry#innovationtechnology#AI#

Advancing Healthcare Innovation and Regulatory Excellence at the 2024 SAAPI Conference At the 2024 SAAPI Conference, held at the CSIR International Convention Centre, SAHPRA CEO Dr. Boitumelo Semete-Makokotlela delivered a compelling keynote address focused on SAHPRA’s mission to provide safe, efficacious, and quality medicines and health products. Emphasizing the importance of patient safety and access, Dr. Semete-Makokotlela highlighted SAHPRA's commitment to being agile and responsive while maintaining high standards of safety, quality, and efficacy. She also stressed the importance of collaboration, indicating that SAHPRA is open to engagement with various stakeholders to improve access to essential health products for South Africans. The conference theme, "Engage and Empower: Pushing the Frontiers of the Pharma Industry," was further explored through presentations by various SAHPRA officials. Discussions covered the reliance approach to medicines registration, safety signal management, and the use of e-signatures to enhance document integrity. The event underscored SAHPRA's dedication to innovative regulatory practices and their efforts to streamline processes, ultimately aiming to foster a responsive and accessible healthcare system. This aligns perfectly with Vicore Health’s commitment to regulatory excellence and innovation. Vicore Health is dedicated to advancing healthcare by supporting regulatory frameworks that enhance drug safety, efficacy, and access, thereby contributing to a robust pharmaceutical industry capable of meeting the evolving healthcare needs of the population. This synergy highlights the potential for greater harmonization and collaboration in the pharmaceutical sector, driving forward shared goals of improving public health outcomes. Find out more here: https://lnkd.in/dBRpPWKf #PharmaInnovation #HealthcareReform #SAAPI2024 #SAHPRA #PatientSafety #RegulatoryExcellence #HealthcareAccess #PharmaIndustry #PublicHealth #Efficacy #QualityMedicines #PharmaceuticalRegulation Read the full article here: https://lnkd.in/eBSzzkZa

How does Health Technology Assessment (HTA) shape the future of patient-centred care?    During Plenary Session 4, our speakers will explore different practices, the potential and challenges of integrating Real World Evidence (RWE) and Real World Data (RWD) in regulatory decisions and HTA. 📢 We will welcome Valentina Strammiello (European Patients' Forum), Kaisa Immonen (European Medicines Agency), Niklas Hedberg (The Dental and Pharmaceutical Benefits Agency, TLV and HTA Coordination Group), Julien Delaye (EURORDIS-Rare Diseases Europe) and Entela Xoxi (ALTEMS Università Cattolica). Check out the full agenda here ➡️ https://lnkd.in/dRMp-mQ4 #DSL5 #DataSavesLives #HealthData #healthcare #patients #HTA

🚀 EU HTAR: Assessing national payers' readiness As the European Union Health Technology Assessment Regulation approaches, how prepared are national payers for this major regulatory change? We examined the readiness of EU Member States and the challenges they are facing as the January 2025 implementation date gets closer. 🔍 Read our article to get more insights: http://skp.link/oon Many thanks to Diane Cosset, Vincent Janssen, Eleonora Sirena and Sara Masutti for their contribution to the article, and to all other Health & Pharma colleagues directly or indirectly involved in our EU HTA Center or excellence! #HealthTech #EUHTAR #Pharma #Healthcare #LifeSciences #SimonKucher

Ready for 2025? How lessons learned from national system reforms can guide our response to the new EU HTA regulations Join us at ISPOR Europe for an engaging symposium as we prepare for the joint clinical assessment (JCA) launching in January 2025. Moderator: Herbert Altmann, Vice President, Market Access & Healthcare Consulting, Cencora Panelists: - Iga Lipska, Chairwoman of the Board, Health Policy Institute Poland - François Meyer, Independent Consultant - Oriol Solà-Morales, CEO, Health Innovation Technology Transfer - Mihai Rotaru, Director, Market Access, European Federation of Pharmaceutical Industries and Associations (EFPIA) Discover how recent reforms in Germany, Spain, France, and Poland can guide our response to new EU regulations. - Insights into the impact of national HTA processes on access and innovation - Strategies for aligning with EU regulations - A blueprint for improving patient outcomes Join us to discuss the future of healthcare access in Europe: https://ow.ly/Kz8h50U2FJF #ISPOR2024 #EUHTA #PatientAccess #MarketAccess

"Safeguarding Against Critical Medicines' Shortage" study update: Results (now in preprint) from incidence and prevalence of medicines with suggested drug shortages and their alternatives were discussed by 70 participants from 20 countries during our first webinar in June. Key take-aways: great learnings of differences between countries, markets, and healthcare settings. The September 5 webinar will address the characteristics of users of medicines with suggested shortages and their alternatives. More about this important from the original post: https://bit.ly/3HA1goV

This week marks a pivotal moment in our work at the Access to Medicine Foundation with the launch of the 2024 Access to Medicine Index #ATMI24. The findings are clear: pharmaceutical innovation is not reaching those who need it most. Only 39% of low-income countries have access to critical pharma supplies, and 43% of new health innovations do not reach Africa. These figures are a stark reminder of the persistent gaps in global health equity. Yet, the Index also sheds light on what’s possible. Inclusive business models, voluntary licenses, and technology transfers are not just theoretical solutions - they are already driving impact in key areas. The 2024 Index showcases numerous best practices and untapped opportunities that, if scaled, could transform access to healthcare worldwide. Let the Access to Medicine Index be your guide. It offers actionable insights to chart the next steps toward a more equitable future in global health. Read the 2024 Index here: https://lnkd.in/e3Aig2FP #ATMI24 #AccesstoMedicine #HealthEquity #EquitableAccess

Did you know that all delegates who are registered to attend the SAPICS 2024 conference can book a seat at a workshop of their choice on Sunday the 9th of June?   Tamara Hafner and Dr Andrew Brown will be presenting Workshop 8: The Nexus of Pharmaceutical Systems and Health Supply Chain Management. What is Needed to Ensure well-functioning supply chains?   Sustainably ensuring equitable access to and appropriate use of safe and quality-assured medicines demands a comprehensive view that situates health supply chains within strong pharmaceutical systems, as a part of the broader health system. USAID MTaPS and its predecessor programs have developed a pharmaceutical system strengthening (PSS) approach that recognizes health supply chains as one of several elements that work in concert to get safe, quality-assured medicines to the population and ensure that they are used appropriately. Participants will learn about the PSS approach and available tools and resources that they can adapt in their health system context.   Learn more about all 11 workshop workshops on offer: https://lnkd.in/dv3_W8yC   The 2024 SAPICS Conference will be held in association with the Southern African Association of Freight Forwarders NPC In view of the demand for workshop attendance and the unfortunate rate of no-shows, there is a non-refundable charge of R350.00 (excl. VAT) per person per workshop. Organised by: Upavon Management Taking place at Century City Conference Centre, Cape Town, South Africa  #SAPICS2024 #SupplyChainMetamorphosis #SupplyChainConference #CapeTown #supplychainmanagement #speakers

Benefits of a clarified #Bolar: ⏰Optimises the regulatory processes 🩺Sustainability of healthcare systems; faster savings for healthcare systems 💡Stimulates innovation 🏭Boosts EU generic & biosimilar manufacturing footprint 💊Timely access, delivering on day 1 after IP expiry = patient access to medicines Find more information in the @Medicines for Europe paper addressing what can be done for #access through the #EUPharmaStrategy review https://lnkd.in/d8536QbU and in our paper on Myths about Bolar https://lnkd.in/dWEMeCKQ